Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Migaldendranib (MGB) in Healthy Volunteers
NCT07370155Phase 1Active, not recruiting
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dendranib (3 arms). Primary endpoint: Safety and Tolerability of MGB at Day 22. Started Jan 2026; status: active, not recruiting.
02
Drugs
dendranib
Beyond the preview
Go deeper on NCT07370155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07370155.